Navigation Links
Varian, Inc. Reports Fourth Quarter 2009 Results
Date:11/4/2009

ng-term debt $ 6,250 $ - Accounts payable 63,368 70,923 Deferred profit 8,935 10,957 Accrued liabilities 171,103 167,173 --------- --------- Total current liabilities 249,656 249,053 Long-term debt 12,500 18,750 Deferred taxes 2,505 4,341 Other liabilities 41,255 43,431 --------- --------- Total liabilities 305,916 315,575 --------- --------- Stockholders' equity Preferred stock-par value $0.01, authorized-1,000 shares; issued-none - - Common stock-par value $0.01, authorized- 99,000 shares; issued and outstanding- 28,971 shares at October 2, 2009 and 28,917 shares at October 3, 2008 368,324 356,192 Retained earnings 220,068 184,678 Accumulated other comprehensive income 49,879 45,471 --------- --------- Total stockholders' equity 638,271 586,341 --------- --------- Total liabilities and stockholders' equity $944,187 $901,916 ========= ========= 
                     VARIAN, INC. AND SUBSIDIARY COMPANIES

             UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
                                (In thousands)

                                   Fiscal Quarter Ended   Fiscal Year Ended
    
'/>"/>
SOURCE  Varian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 

Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Polymer with honeycomb structure 14947 1Polymer with honeycomb structure 14947 2Family Health History and Genetics Privacy is the Newest Addition to the ACMG Genetics 26amp 3B Your Health Video Series 61991 1Family Health History and Genetics Privacy is the Newest Addition to the ACMG Genetics 26amp 3B Your Health Video Series 61991 2Pennsylvania Agriculture Department Encourages Proper Food Handling Offers Safety Tips for Thanksgiving 61989 1Pennsylvania Agriculture Department Encourages Proper Food Handling Offers Safety Tips for Thanksgiving 61989 2